Publication: Genome-wide gene-by-smoking interaction study of chronic obstructive pulmonary disease
Issued Date
2021-01-01
Resource Type
ISSN
14766256
00029262
00029262
Other identifier(s)
2-s2.0-85105284841
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Epidemiology. Vol.190, No.5 (2021), 875-885
Suggested Citation
Woori Kim, Dmitry Prokopenko, Phuwanat Sakornsakolpat, Brian D. Hobbs, Sharon M. Lutz, John E. Hokanson, Louise V. Wain, Carl A. Melbourne, Nick Shrine, Martin D. Tobin, Edwin K. Silverman, Michael H. Cho, Terri H. Beaty Genome-wide gene-by-smoking interaction study of chronic obstructive pulmonary disease. American Journal of Epidemiology. Vol.190, No.5 (2021), 875-885. doi:10.1093/aje/kwaa227 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78755
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Genome-wide gene-by-smoking interaction study of chronic obstructive pulmonary disease
Abstract
Risk of chronic obstructive pulmonary disease (COPD) is determined by both cigarette smoking and genetic susceptibility, but little is known about gene-by-smoking interactions. We performed a genome-wide association analysis of 179,689 controls and 21,077 COPD cases from UK Biobank subjects of European ancestry recruited from 2006 to 2010, considering genetic main effects and gene-by-smoking interaction effects simultaneously (2-degrees-of-freedom (df) test) as well as interaction effects alone (1-df interaction test). We sought to replicate significant results in COPDGene (United States, 2008.2010) and SpiroMeta Consortium (multiple countries, 1947.2015) data. We considered 2 smoking variables: 1) ever/never and 2) current/noncurrent. In the 1-df test, we identified 1 genome-wide significant locus on 15q25.1 (cholinergic receptor nicotinic β4 subunit, or CHRNB4) for ever- and current smoking and identified PI∗Z allele (rs28929474) of serpin family A member 1 (SERPINA1) for ever-smoking and 3q26.2 (MDS1 and EVI1 complex locus, or MECOM) for current smoking in an analysis of previously reported COPD loci. In the 2-df test, most of the significant signals were also significant for genetic marginal effects, aside from 16q22.1 (sphingomyelin phosphodiesterase 3, or SMPD3) and 19q13.2 (Egl-9 family hypoxia inducible factor 2, or EGLN2). The significant effects at 15q25.1 and 19q13.2 loci, both previously described in prior genome-wide association studies of COPD or smoking, were replicated in COPDGene and SpiroMeta. We identified interaction effects at previously reported COPD loci; however, we failed to identify novel susceptibility loci.